The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies

PLoS Medicine

Volumn 10, Issue 3, 2013, Pages

  Gomez, Gabriela B ^a   Borquez, Annick ^b   Case, Kelsey K ^b   Wheelock, Ana ^b   Vassall, Anna ^c   Hankins, Catherine ^a,c  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE;

BEHAVIOR CHANGE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DATA EXTRACTION; EPIDEMIC; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; PERU; POPULATION RISK; PROPHYLAXIS; REVIEW; SEXUAL BEHAVIOR; SYSTEMATIC REVIEW; TOXICITY; UKRAINE; UNITED STATES; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; EPIDEMICS; HETEROSEXUALITY; HIV INFECTIONS; HUMANS; MALE; MODELS, ECONOMIC; PERU; SOUTH AFRICA; SUBSTANCE ABUSE, INTRAVENOUS; UKRAINE; UNITED STATES;

EID: 84875470987     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001401     Document Type: Review

References (51)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423-434.
4. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411-422.
5. NIH (2011) NIH modifies 'VOICE' HIV prevention study in women: oral tenofovir discontinued in clinical trial. Available: http://www.nih.gov/news/health/sep2011/niaid-28.htm). Bethesda: National Institute of Allergy and Infectious Diseases. Accessed 11 February 2013.
6. Facts Consortium (2013) FACTS001 Available: http://www.facts-consortium.co.za/. Accessed 11 February 2013.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
8. MTN (2011) MTN statement on decision to discontinue use of tenofovir gel in VOICE, major prevention study in women. Available: http://www.mtnstopshiv.org/node/3909). Pittsburgh: Microbicide Trials Network. Accessed 11 February 2013.
9. CDC (2011) Interim guidance: preexposure prophylaxis for the prevention of hiv infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 60: 65-68.
10. McCormack S, Fidler S, Fisher M, (2012) The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK. Int J STD AIDS 23: 1-4.
11. The Consensus Committee SAHCS (2012) Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. S Afr J HIV Med 13: 40-55.
12. WHO (2012) Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Available: http://www.who.int/hiv/pub/guidance_prep/en/index.html). Geneva. Accessed 11 February 2013.
13. CDC (2012) Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep 61: 586-589.
14. Morgan D (2012) FDA panel backs Gilead's Truvada to prevent HIV. Washington (D.C.): Reuters: http://www.reuters.com/article/2012/05/11/us-usa-aids-truvada-idUSBRE84A00C20120511. Accessed 11 February 2013.
15. Schwartlander B, Stover J, Hallett T, Atun R, Avila C, et al. (2011) Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 377: 2031-2041.
16. Wheelock A, Eisingerich AB, Gomez GB, Gray E, Dybul MR, et al. (2012) Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. BMJ Open 2: e001234.
17. Krakower D, Mayer KH, (2012) Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS 7: 593-599.
18. Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, et al. (2012) A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 7: e40603 doi:10.1371/journal.pone.0040603.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097 doi:10.1371/journal.pmed.1000097.
20. Drummond MF, Jefferson TO, (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313: 275-283.
21. Kumaranayake L, (2000) The real and the nominal? Making inflationary adjustments to cost and other economic data. Health Policy Plan 15: 230-234.
22. WHO-CHOICE (2012) Cost effectiveness thresholds: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 11 February 2013.
23. World Bank (2012) GDP per capita (current US$). Available: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
24. Shillcutt SD, Walker DG, Goodman CA, Mills AJ, (2009) Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 27: 903-917.
25. Abbas UL, Anderson RM, Mellors JW, (2007) Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2: e875 doi:10.1371/journal.pone.0000875.
26. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839.
27. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, et al. (2012) The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men in Lima, Peru. PLoS Med 9: e1001323 doi:10.1371/journal.pmed.1001323.
28. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, et al. (2011) Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8: e1001123 doi:10.1371/journal.pmed.1001123.
29. Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL, (2011) The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr 58: e51-e52.
30. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B, (2010) Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 5: e13646 doi:10.1371/journal.pone.0013646.
31. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, et al. (2012) The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 54: 1504-1513.
32. Williams BG, Abdool Karim SS, Karim QA, Gouws E, (2011) Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 58: 207-210.
33. Alistar SS (2011) TR2-2: Effectiveness and cost-effectiveness of oral pre-exposure prophylaxis for injection drug users in mixed HIV epidemics. Available: http://smdm.confex.com/smdm/2011ch/webprogram/Paper6553.html). 33rd Annual Meeting of the Society for Medical Decision Making, Hillsborough, USA. Accessed 11 February 2013.
34. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806-815.
35. Juusola JL, Brandeau ML, Owens DK, Bendavid E, (2012) The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 156: 541-550.
36. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, et al. (2013) The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. Aids 27: 447-458.
37. Alistar SS, Grant P, Bendavid E (2012) Paper #1081- An economic analysis of ART and PrEP for HIV prevention: South Africa. Available: http://www.retroconference.org/2012b/Abstracts/44724.htm). 19th Conference on Retroviruses and Opportunistic Infections. Seattle. Accessed 11 February 2013.
38. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoowong R, et al. (2011) Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One 6: e25127 doi:10.1371/journal.pone.0025127.
39. Keller SB, Smith DM, (2011) The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. Aids 25: 2308-2310.
40. Lee DH, Vielemeyer O, (2011) Preexposure chemoprophylaxis for HIV prevention. N Engl J Med 364: 1372-1373 author reply 1374-1375.
41. iPrEXOle (2012) Press release. Available: http://www.iprexnews.com/pdfswhatisnew/closedenrollment/iPrEx%20OLE%20Fully%20Enrolled%20-%2001JUL12.pdf. Accessed 11 February 2013.
42. Vernazza PL, Graf I, Sonnenberg-Schwan U, Geit M, Meurer A, (2011) Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. Aids 25: 2005-2008.
43. Matthews LT, Baeten JM, Celum C, Bangsberg DR, (2010) Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. Aids 24: 1975-1982.
44. Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, et al. (2012) Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One 7: e33103 doi:10.1371/journal.pone.0033103.
45. IPERGAY: un essai ANRS (2013) ANRS Intervention Preventive de l'Exposition aux Risques avec et pour les GAYS. Available: http://www.ipergay.fr/. Accessed 11 February 2013.
46. HPTN (2013) HPTN 067: ADAPT study, a phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). http://www.hptn.org/research_studies/hptn067.asp. Accessed 11 February 2013.
47. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, et al. (2012) Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One 7: e28238 doi:10.1371/journal.pone.0028238.
48. Simpson KN, (2010) Economic modeling of HIV treatments. Curr Opin HIV AIDS 5: 242-248.
49. Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret A, et al. (2009) Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One 4: e5272 doi:10.1371/journal.pone.0005272.
50. Tengs TO, Lin TH, (2002) A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 22: 475-481.
51. Verguet S, Walsh JA, (2010) Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Sex Transm Infect 86: 212-216.